AzTrials
AzTrials

Chronic Obstructive Pulmonary DiseaseNCT00792974

End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)

An observational study of Chronic Obstructive Pulmonary Disease and End-of-Life Fear, run by Philipps University Marburg at 2 sites in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life. Afterwards, the patients receive a brief psychological intervention to develop coping strategies for chronic illness. Read more about this study

Who is it for?
Ages 50 to 75 yearsHealthy volunteers can take part
What is being tested?
A brief psycho-educational intervention
How many people
199 participants
Where
2 sitesGermany
Study dates
Oct 2008to Jul 2010
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use auf administrative databases. All patients who are alert and can provide consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons in match-able age.

Who may be able to join

  • 50 years or older
  • COPD diagnosis III and IV by GOLD-criteria with or without an indication for long-term oxygen therapy (LTOT), non invasive ventilation (NIV) and/or lung transplantation (LTx)
  • COPD diagnosis II by GOLD-criteria
  • Patients with hip prosthesis
  • Mental healthy people, who have no severe illness (such as heart disease or cancer) one year before

Who cannot join

  • Participation in other studies likely to influence the patient in terms of confounding effects
  • Acute and severe exacerbations with hard symptoms over 4 days
  • Patients need a increasing medication of steroids and/or antibiotics
  • Non-compliance

Trial locations and contacts

2 sites in 1 country.

Winfried Rief, Prof. Dr. contact

+49-6421-2823657

rief@staff.uni-marburg.de

Sabine R Pinzer, Dipl.-Psych. contact

spinzer@schoen-kliniken.de

Germany2 sites, 2 recruiting
  • Department of Clinical Psychology and Psychotherapy, Philipps University Marburg

    Marburg, 35032

    Winfried Rief, Prof. Dr., rief@staff.uni-marburg.de

    Sabine R Pinzer, Dipl.-Psych., pinzer@staff.uni-marburg.de

    Recruiting
  • Klinikum Berchtesgadener Land, Schön Kliniken

    Schönau am Königssee, 83471

    Klaus Kenn, Dr., kkenn@schoen-kliniken.de

    Sabine R Pinzer, Dipl.-Psych., spinzer@schoen-kliniken.de

    Recruiting

Other trials in Germany

About this study

Official title: End-of-Life Fear in Patients With End-Stage Lung Disease: Fears of Death and Dying, Wishes and Needs of Patients With Severe COPD

The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life. Afterwards, the patients receive a brief psychological intervention to develop coping strategies for chronic illness. Beside this a general purpose of this intervention is to improve patients' quality of life.

Read the detailed description

Background:

COPD-related mortality differs markedly from that of other chronic diseases. While the mortality rates for heart disease and stroke have fallen significantly, death rates caused by COPD have more than doubled. Therefore there is a major need to address questions of palliative end-of-life care. Patients with end-stage pulmonary lung diseases suffer from dyspnea, severe pain, fatigue and - the "deadlock" in end-of-life communication. Many people with severe COPD are socially isolated, have low quality of life and psychosocial challenges such as sadness, panic or hopelessness. In fact, 70 up to 90% suffer from a clinically relevant depression and/or anxiety disorder. Despite this, the majority of COPD patients with co-morbid disorders don't receive any treatment for their psychological symptoms. Furthermore, there is substantial evidence that only a minority of people with end-stage COPD have the opportunity to discuss their fears and wishes for end-of-life care. The few existing studies on this issue demonstrated that the majority of people with severe COPD wants to discuss topics such as prognosis, fear of death and dying or preferences and needs at the end-of-life. Understanding the nature and implications of treatment options is an important component of advanced care planning for people with end-stage lung disease.

Therefore the aim of this study is to bring up the end-of-life communication to patients with end-stage COPD. We hypothesize that end-stage COPD patients have greater fear of death and dying as patients with mild to moderate COPD or with hip prothesis (control group). The lowest anxiety rate with regard to death should be found in the healthy control group. Furthermore, a brief psychological intervention should decrease the co-morbid psychological symptoms and patients' fears. Higher quality of life should be achieved.

Objectives:

Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use of administrative databases. All patients providing informed consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons matched for age and sex. As we want to start a first feasibility intervention study, this is a clinical controlled design without randomization.

Methods:

Initially a systematic literature review was performed to determine what methods are being used in COPD studies and how the patients' views can be best assessed. Then a qualitative multi-method design will be used involving semi-structured interviews, standardized questionnaires and lung function parameters.

The face-to-face interview includes ten categories with more than 70 questions on

  1. social demography
  2. actual health status
  3. knowledge and wishes of further information about the disease
  4. thoughts and attitudes about the illness
  5. fears about the illness, treatment and prognosis
  6. general experiences of death and dying
  7. own experiences with death and dying
  8. fear of death
  9. fear of dying
  10. end-of-life decisions such as wishes and needs

Patients will be interviewed by a single interviewer. Each question will be read by using everyday language. Interviews will be audiotaped to control for integrity. Each interview will last approximately 60 minutes. The interview will be validated by the COPD-Anxiety-Questionnaire (CAF). To assess the patients cognitions about death, a self-report questionnaire, FIMEST, will be also used.

Standardized questionnaires will be used to detect depression or panic disorders by the Hospital Anxiety and Depression Scale. Functional health status will be measured by the Patients Health Questionnaire (PHQ) and the COPD-Disability- Index (CDI). The condition specific questionnaire, the Short Form-36 Health Survey (SF-36) and Euroqol (EQ) will be compared for their discriminative and evaluative properties. Spirometric tests and a walking test will be also performed.

After the interview those patients who have increased death anxiety take part in a brief psychological intervention to discuss their end-of-life issues, worries and fears. For this psychological intervention, a manualized 2-3-session approach will be used.

Being tested
A brief psycho-educational intervention
Keywords
Cognitive behavioral education, COPD (Chronic Obstructive Pulmonary Disease), GOLD II-IV
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • A brief psycho-educational interventionBehavioural

    Also called Cognitive-behavioral therapy, Palliative care

    A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.

    This study is an open pilot study ("feasibility study") to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment.

Study groups in NCT00792974
Study groupRoleWhat they receive
COPD by GOLD-criteria III and IVNot described
Receives: Behavioral: A brief psycho-educational intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Self-reported semi-structured interview about the fear of death and dying, needs and wishes at the end-of-life in patients with severe COPD

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

Secondary outcomes (17)
  1. St. George's Respiratory Questionnaire (SGRQ)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  2. Short Form Health Survey (Fragebogen zum allgemeinen Gesundheitszustand, SF-36)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  3. Euroqol (EQ)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  4. Patient Health Questionnaire (PHQ)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  5. Hospital Anxiety and Depression Scale (HADS)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  6. Borg Scale

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  7. Diffusion capacity (DLCO)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  8. Blood gas analysis (BGA)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  9. Bodyplethysmographs

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  10. Bio-Impedance-Analysis (BIA)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  11. 6-Minute Walk Distance (6 MWD)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  12. Body Mass Index (BMI)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  13. Blood tests

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  14. Multidimensional assessment of attitudes toward death and dying (Fragebogeninventar zur mehrdimensionalen Erfassung des Erlebens gegenüber Sterben und Tod, FIMEST)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  15. COPD- Anxiety -Questionnaire (COPD-Angst-Fragebogen, CAF)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  16. COPD- Disability- Index (CDI)

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

  17. Differences in COPD admission rates, functional impairment, quality of life and end-of-life fear after treatment

    Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2008 (estimated)
  2. Study startOct 2008
  3. Primary completionJul 2010 (estimated)
  4. Study completionJul 2010 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
199 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00792974
Sponsor's protocol ID
EoL
Status last verified
Feb 2009
First submitted
17 Nov 2008
Last updated
5 Feb 2009
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Obstructive Pulmonary Disease and End-of-Life Fear, run by Philipps University Marburg at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Winfried Rief, Prof. Dr. (+49-6421-2823657, rief@staff.uni-marburg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Self-reported semi-structured interview about the fear of death and dying, needs and wishes at the end-of-life in patients with severe COPD (time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in